Oral Brepocitinib

Preclinical

PPriovant Therapeutics, Inc.

Oral Brepocitinib is one of 9 therapeutic programs targeting Lichen Planopilaris. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lichen PlanopilarisRecruiting

Lichen PlanopilarisPreclinical

Recruiting

Competition

Competitive Landscape

10 competitors in Lichen Planopilaris

#DrugCompanyPhaseTrials

Rezzayo

Roche

Approved

1 2

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Rinvoq

1 4

Cosentyx

Taltz

1 6

Low-Dose Naltrexone

SStanford University

Phase 2

1 7

Trexall

Alnylam Pharmaceuticals

Preclinical

1 8

Plaquenil

Alnylam Pharmaceuticals

Preclinical

1 9

Oral Brepocitinib

PPriovant Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Lichen Planopilaris

NCT07532603

Clinical

Trials by Indication[1]

Lichen Planopilaris1 trial

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris

Recruiting·PPriovant Therapeutics, Inc.·Preclinical·NCT07532603·342 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral Brepocitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral Brepocitinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Priovant Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: PPriovant Therapeutics, Inc.

Oral Brepocitinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Lichen Planopilaris1 trial

References

Drug Info

Quick Facts

Related News